Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
Study Counts
| Total_Studies |
1371 |
| interventional |
1019 |
| Observational |
316 |
| Registry |
36 |
Interventional Trials
Intervention Type
| Behavioral |
258 |
| Drug|placebo |
164 |
| Other |
150 |
| Drug |
135 |
| Device |
107 |
| Dietary Supplement|placebo |
37 |
| Procedure |
24 |
| Dietary Supplement |
19 |
| Behavioral|Other |
12 |
| Drug|Other |
12 |
| Behavioral|Device |
10 |
| Behavioral|placebo |
10 |
| Device|Other |
6 |
| Behavioral|Drug|placebo |
5 |
| Device|Drug |
5 |
| Diagnostic Test |
5 |
| Behavioral|Drug |
4 |
| Device|placebo |
4 |
| Dietary Supplement|Other |
4 |
| Drug|Procedure |
4 |
| Other|placebo |
4 |
| Behavioral|Dietary Supplement|placebo |
3 |
| Biological |
3 |
| Biological|placebo |
3 |
| Combination Product |
3 |
| Behavioral|Dietary Supplement |
2 |
| Combination Product|placebo |
2 |
| Dietary Supplement|Other|placebo |
2 |
| Drug|Other|placebo |
2 |
| Other|Radiation |
2 |
| Behavioral|Dietary Supplement|Other |
1 |
| Behavioral|Drug|Other |
1 |
| Behavioral|Drug|Other|Radiation |
1 |
| Behavioral|Drug|placebo|Procedure |
1 |
| Behavioral|Drug|Procedure |
1 |
| Behavioral|Procedure |
1 |
| Behavioral|Radiation |
1 |
| Biological|Other |
1 |
| Biological|Other|Procedure |
1 |
| Device|Drug|placebo |
1 |
| Device|Drug|Radiation |
1 |
| Device|Other|Radiation |
1 |
| Device|Procedure |
1 |
| Diagnostic Test|Procedure |
1 |
| Dietary Supplement|Drug |
1 |
| Dietary Supplement|Drug|placebo |
1 |
| Drug|Radiation |
1 |
| Radiation |
1 |
Count of Studies by Intervention (normalized and mapped)
Interventions over Time
Weekly studies for each intervention
Studies by Country
| United States |
461 |
| Canada |
70 |
| NA |
57 |
| China |
53 |
| Taiwan |
30 |
| France |
28 |
| Germany |
24 |
| Italy |
23 |
| United Kingdom |
22 |
| Spain |
20 |
| Korea, Republic of |
18 |
| Netherlands |
14 |
| Switzerland |
13 |
| Brazil |
12 |
| Denmark |
11 |
| Belgium |
8 |
| Israel |
8 |
| Norway |
8 |
| Singapore |
8 |
| Australia |
7 |
| Hong Kong |
6 |
| Japan |
6 |
| Sweden |
6 |
| Czechia |
5 |
| Turkey |
5 |
| Egypt |
4 |
| Mexico |
4 |
| Portugal |
4 |
| Russian Federation |
4 |
| United States|Canada |
4 |
| Greece |
3 |
| Thailand |
3 |
| Austria |
2 |
| Croatia |
2 |
| India |
2 |
| Malaysia |
2 |
| Pakistan |
2 |
| United States|Italy |
2 |
| United States|Spain |
2 |
| Argentina |
1 |
| Australia|Hong Kong |
1 |
| Australia|Netherlands |
1 |
| Austria|Croatia|Germany|Serbia|Spain |
1 |
| Austria|Germany|Israel |
1 |
| Belarus|Kazakhstan|Russian Federation |
1 |
| Belgium|Canada|Switzerland |
1 |
| Belgium|Czechia|Spain|Sweden |
1 |
| Belgium|Netherlands |
1 |
| Bulgaria|United States|Finland|Germany|Poland|Russian Federation|Ukraine |
1 |
| China|Hong Kong |
1 |
| Czechia|Germany|Hungary|Netherlands|Spain|United Kingdom |
1 |
| Denmark|Italy|Netherlands|Sweden|United Kingdom |
1 |
| Estonia|Finland|Germany|Lithuania |
1 |
| Estonia|Finland|Germany|Serbia|Slovakia |
1 |
| Finland|Netherlands|United Kingdom |
1 |
| France|Germany|Greece|Italy|Netherlands|Spain |
1 |
| France|Germany|Spain|United Kingdom |
1 |
| France|Italy|Spain|Sweden |
1 |
| France|Monaco |
1 |
| Germany|Ireland|Netherlands |
1 |
| Germany|United Kingdom |
1 |
| Hungary |
1 |
| Ireland |
1 |
| Jamaica |
1 |
| Lebanon |
1 |
| New Zealand |
1 |
| Philippines |
1 |
| Philippines|Singapore|Vietnam |
1 |
| Poland |
1 |
| Romania|Spain |
1 |
| Serbia |
1 |
| Slovakia |
1 |
| Slovakia|Taiwan |
1 |
| Slovenia |
1 |
| Uganda |
1 |
| Ukraine |
1 |
| United Kingdom|United States|Argentina|Australia|Brazil|Colombia|Italy|Mexico|Poland|Romania|Russian Federation|Ukraine |
1 |
| United States|Argentina|Australia|Belgium|Canada|Colombia|Germany|Italy|Mexico|Poland|Romania|Russian Federation|Singapore|Spain|Ukraine|United Kingdom |
1 |
| United States|Argentina|Australia|Brazil|Canada|Germany|Mexico|Poland|Russian Federation|Serbia|Singapore|Spain|Ukraine |
1 |
| United States|Australia|Canada|France|Mexico|Spain|United Kingdom |
1 |
| United States|Australia|France |
1 |
| United States|Australia|Spain |
1 |
| United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Poland|Portugal|United Kingdom |
1 |
| United States|Austria|Canada|Finland|France|Germany|Greece|Hungary|Italy|Japan|Norway|Poland|Spain|United Kingdom |
1 |
| United States|Canada|France|Germany|Italy|Spain|Switzerland |
1 |
| United States|Canada|United Kingdom |
1 |
| United States|China|Israel |
1 |
| United States|France|Italy |
1 |
| United States|Hungary|Romania|Russian Federation|Serbia|Ukraine |
1 |
| United States|India |
1 |
| United States|Ireland|Singapore |
1 |
| United States|Japan |
1 |
| United States|Japan|United Kingdom |
1 |
| United States|Russian Federation|United Kingdom |
1 |
| United States|Switzerland |
1 |
Sites per Study
| 1 |
772 |
| 2 |
85 |
| 3 |
31 |
| 4 |
21 |
| 5 |
12 |
| 6 |
9 |
| 7 |
2 |
| 8 |
7 |
| 9 |
5 |
| 10 |
2 |
| 11 |
2 |
| 12 |
4 |
| 13 |
6 |
| 14 |
4 |
| 15 |
2 |
| 16 |
4 |
| 17 |
3 |
| 18 |
3 |
| 19 |
1 |
| 20 |
3 |
| 23 |
3 |
| 24 |
4 |
| 25 |
2 |
| 26 |
1 |
| 27 |
1 |
| 28 |
4 |
| 29 |
1 |
| 30 |
2 |
| 31 |
1 |
| 37 |
1 |
| 42 |
1 |
| 45 |
1 |
| 47 |
1 |
| 49 |
1 |
| 54 |
1 |
| 57 |
1 |
| 60 |
1 |
| 61 |
1 |
| 64 |
1 |
| 72 |
1 |
| 77 |
1 |
| 92 |
1 |
| 94 |
1 |
| 95 |
1 |
| 104 |
1 |
| 107 |
1 |
| 129 |
1 |
| 145 |
1 |
| 220 |
1 |
| 256 |
1 |
| 262 |
1 |
Phase
| N/A |
639 |
| Phase 2 |
143 |
| Phase 4 |
85 |
| Phase 3 |
58 |
| Phase 1 |
44 |
| Phase 1/Phase 2 |
19 |
| Early Phase 1 |
16 |
| Phase 2/Phase 3 |
15 |
Number of Arms
| 1 |
121 |
| 2 |
619 |
| 3 |
149 |
| 4 |
70 |
| 5 |
11 |
| 6 |
8 |
| 7 |
2 |
| 8 |
2 |
| 9 |
3 |
| 10 |
1 |
| 14 |
1 |
| 21 |
1 |
| NA |
31 |
Number of Updates
| 1 |
117 |
| 2 |
156 |
| 3 |
156 |
| 4 |
144 |
| 5 |
91 |
| 6 |
66 |
| 7 |
66 |
| 8 |
54 |
| 9 |
39 |
| 10 |
22 |
| 11 |
19 |
| 12 |
15 |
| 13 |
15 |
| 14 |
10 |
| 15 |
13 |
| 16 |
4 |
| 17 |
3 |
| 18 |
8 |
| 20 |
5 |
| 21 |
2 |
| 22 |
1 |
| 23 |
1 |
| 24 |
1 |
| 25 |
1 |
| 28 |
1 |
| 31 |
1 |
| 39 |
1 |
| 40 |
1 |
| 41 |
1 |
| 46 |
1 |
| 62 |
1 |
| 63 |
2 |
| 82 |
1 |
Update History Change Type
| Study Status |
4602 |
902 |
5.101996 |
| Contacts/Locations |
1987 |
746 |
2.663539 |
| Recruitment Status |
1169 |
743 |
1.573351 |
| None (earliest Version on record) |
1019 |
1019 |
1.000000 |
| Study Design |
828 |
581 |
1.425129 |
| Outcome Measures |
703 |
462 |
1.521645 |
| Eligibility |
576 |
375 |
1.536000 |
| Arms |
509 |
350 |
1.454286 |
| Interventions |
509 |
350 |
1.454286 |
| Study Description |
490 |
348 |
1.408046 |
| Sponsor/Collaborators |
456 |
309 |
1.475728 |
| Study Identification |
402 |
265 |
1.516981 |
| Oversight |
297 |
257 |
1.155642 |
| Conditions |
194 |
153 |
1.267974 |
| References |
135 |
100 |
1.350000 |
| Results |
125 |
125 |
1.000000 |
| IPDSharing |
113 |
99 |
1.141414 |
| Results Submission Events |
77 |
77 |
1.000000 |
| More Information |
71 |
45 |
1.577778 |
| Documents |
45 |
43 |
1.046512 |
| Baseline Characteristics |
21 |
17 |
1.235294 |
| Reported Adverse Events |
12 |
12 |
1.000000 |
| Participant Flow |
8 |
7 |
1.142857 |
Enrollment Metrics by Phase
| Min. |
5.0000 |
2.0000 |
5.00000 |
5.00000 |
5.0000 |
10.0000 |
12.0000 |
7.0000 |
| 1st Qu. |
16.0000 |
40.0000 |
22.75000 |
20.00000 |
48.5000 |
44.0000 |
100.0000 |
40.0000 |
| Median |
20.0000 |
70.0000 |
33.50000 |
32.00000 |
88.0000 |
70.0000 |
245.0000 |
78.0000 |
| Mean |
35.9375 |
211.7355 |
51.52273 |
42.47368 |
134.4126 |
151.2667 |
346.2143 |
230.7529 |
| 3rd Qu. |
51.0000 |
150.0000 |
64.25000 |
56.50000 |
172.5000 |
240.0000 |
526.0000 |
222.0000 |
| Max. |
143.0000 |
14641.0000 |
414.00000 |
166.00000 |
1768.0000 |
513.0000 |
1584.0000 |
3300.0000 |
Trial Group Type
| Experimental |
1109 |
| Active Comparator |
487 |
| Placebo Comparator |
298 |
| No Intervention |
173 |
| Other |
128 |
| Sham Comparator |
96 |
| NA |
31 |
Intervention Model
| Parallel Assignment |
745 |
| Single Group Assignment |
147 |
| Crossover Assignment |
99 |
| Factorial Assignment |
21 |
| Sequential Assignment |
6 |
| NA |
1 |
Primary Purpose
| Treatment |
527 |
| Prevention |
208 |
| Supportive Care |
77 |
| Diagnostic |
57 |
| Other |
49 |
| Basic Science |
48 |
| Health Services Research |
21 |
| Screening |
16 |
| NA |
14 |
| Device Feasibility |
2 |
Observational Studies
Studies by Country
| United States |
107 |
| China |
27 |
| NA |
18 |
| Canada |
17 |
| Germany |
15 |
| Denmark |
14 |
| France |
11 |
| Italy |
11 |
| Switzerland |
9 |
| Egypt |
8 |
| United Kingdom |
8 |
| Norway |
7 |
| Israel |
5 |
| Belgium |
4 |
| Korea, Republic of |
4 |
| Netherlands |
4 |
| Spain |
4 |
| Austria |
3 |
| Hong Kong |
3 |
| Singapore |
3 |
| Sweden |
3 |
| Taiwan |
3 |
| Turkey |
3 |
| United States|Canada |
3 |
| Finland |
2 |
| Indonesia |
2 |
| Poland |
2 |
| Australia |
1 |
| Australia|Germany|Spain|Sweden |
1 |
| Canada|Netherlands|Sweden |
1 |
| Cyprus |
1 |
| France|Italy |
1 |
| France|Japan |
1 |
| Iceland |
1 |
| Lithuania |
1 |
| Malaysia |
1 |
| Portugal |
1 |
| Russian Federation |
1 |
| Tanzania |
1 |
| Thailand |
1 |
| United States|Argentina|Australia|Austria|Belgium|Canada|Czech Republic|Finland|France|Germany|Israel|Netherlands|Poland|Spain|Sweden|United Kingdom |
1 |
| United States|Puerto Rico |
1 |
| United States|Spain |
1 |
Sites per Study
| 1 |
264 |
| 2 |
23 |
| 3 |
5 |
| 4 |
4 |
| 5 |
3 |
| 6 |
2 |
| 7 |
1 |
| 8 |
1 |
| 9 |
3 |
| 12 |
2 |
| 16 |
1 |
| 19 |
2 |
| 25 |
1 |
| 55 |
1 |
| 58 |
1 |
| 59 |
1 |
| 145 |
1 |
Number of Updates
| 1 |
46 |
| 2 |
62 |
| 3 |
47 |
| 4 |
47 |
| 5 |
33 |
| 6 |
22 |
| 7 |
11 |
| 8 |
12 |
| 9 |
6 |
| 10 |
7 |
| 11 |
3 |
| 12 |
4 |
| 13 |
3 |
| 14 |
2 |
| 16 |
1 |
| 17 |
1 |
| 22 |
1 |
| 23 |
1 |
| 27 |
1 |
| 48 |
1 |
| 59 |
1 |
| 80 |
1 |
| 88 |
1 |
| 120 |
1 |
| 676 |
1 |
Update History Change Type
| Study Status |
2095 |
270 |
7.759259 |
| Contacts/Locations |
566 |
200 |
2.830000 |
| None (earliest Version on record) |
316 |
316 |
1.000000 |
| Recruitment Status |
295 |
196 |
1.505102 |
| Study Design |
219 |
158 |
1.386076 |
| Outcome Measures |
158 |
115 |
1.373913 |
| Eligibility |
139 |
89 |
1.561798 |
| Study Description |
123 |
86 |
1.430233 |
| Sponsor/Collaborators |
113 |
85 |
1.329412 |
| Study Identification |
112 |
79 |
1.417722 |
| Groups |
102 |
68 |
1.500000 |
| Interventions |
102 |
68 |
1.500000 |
| Oversight |
74 |
66 |
1.121212 |
| Conditions |
54 |
41 |
1.317073 |
| References |
48 |
31 |
1.548387 |
| IPDSharing |
21 |
20 |
1.050000 |
| Results |
10 |
10 |
1.000000 |
| More Information |
9 |
4 |
2.250000 |
| Results Submission Events |
6 |
6 |
1.000000 |
| Documents |
5 |
3 |
1.666667 |
| Reported Adverse Events |
2 |
1 |
2.000000 |
| Baseline Characteristics |
1 |
1 |
1.000000 |
| Participant Flow |
1 |
1 |
1.000000 |
Enrollment Metrics
| Min |
6.0000 |
| 1st Qu |
69.0000 |
| Median |
150.0000 |
| Mean |
629.8354 |
| 3rd Qu |
400.0000 |
| Max |
25240.0000 |
Observation Model
| Cohort |
184 |
| Case-Control |
54 |
| Case-Only |
28 |
| Case Control |
18 |
| Other |
18 |
| NA |
5 |
| Case-Crossover |
4 |
| Ecologic or Community |
4 |
| Natural History |
1 |
Time Perspective
| Prospective |
254 |
| Cross-Sectional |
39 |
| Retrospective |
16 |
| Other |
5 |
| Longitudinal, Prospective |
1 |
| NA |
1 |
Registries
Studies by Country
| China |
9 |
| United States |
5 |
| Hong Kong |
3 |
| Belgium |
2 |
| Egypt |
2 |
| Germany |
2 |
| NA |
2 |
| Taiwan |
2 |
| Turkey |
2 |
| Canada |
1 |
| Denmark |
1 |
| Ecuador |
1 |
| Finland |
1 |
| France |
1 |
| Korea, Republic of |
1 |
| Spain |
1 |
Number of Updates
| 1 |
11 |
| 2 |
6 |
| 3 |
6 |
| 4 |
6 |
| 5 |
4 |
| 6 |
1 |
| 7 |
1 |
| 8 |
1 |
Update History Change Type
| Study Status |
70 |
25 |
2.800000 |
| None (earliest Version on record) |
36 |
36 |
1.000000 |
| Contacts/Locations |
24 |
16 |
1.500000 |
| Recruitment Status |
20 |
17 |
1.176471 |
| Outcome Measures |
10 |
9 |
1.111111 |
| Study Design |
10 |
10 |
1.000000 |
| Study Description |
9 |
8 |
1.125000 |
| Groups |
7 |
7 |
1.000000 |
| Interventions |
7 |
7 |
1.000000 |
| Oversight |
6 |
6 |
1.000000 |
| Eligibility |
5 |
5 |
1.000000 |
| Study Identification |
5 |
5 |
1.000000 |
| Sponsor/Collaborators |
3 |
3 |
1.000000 |
| Conditions |
1 |
1 |
1.000000 |
| Documents |
1 |
1 |
1.000000 |
| IPDSharing |
1 |
1 |
1.000000 |
Enrollment Metrics
| Min |
30.000 |
| 1st Qu |
100.000 |
| Median |
500.000 |
| Mean |
1856.667 |
| 3rd Qu |
973.750 |
| Max |
25000.000 |
Registry Model
| Cohort |
20 |
| Case-Control |
9 |
| Case-Only |
4 |
| Other |
3 |
Time Perspective
| Prospective |
28 |
| Cross-Sectional |
7 |
| Other |
1 |
Follow-up
| 5 Years |
5 |
| 1 Day |
4 |
| 2 Years |
4 |
| 6 Months |
3 |
| 1 Month |
2 |
| 12 Months |
2 |
| 2 Months |
2 |
| 3 Years |
2 |
| 1 Year |
1 |
| 10 Years |
1 |
| 18 Months |
1 |
| 2 Days |
1 |
| 2 Weeks |
1 |
| 20 Years |
1 |
| 24 Months |
1 |
| 25 Years |
1 |
| 3 Months |
1 |
| 36 Months |
1 |
| 4 Weeks |
1 |
| 9 Months |
1 |